Did you know? Residual inflammatory risk — independent of LDL cholesterol — contributes significantly to recurrent cardiovascular events after myocardial infarction. The LoDoCo2 Phase 3 trial (n=5,522 patients with chronic coronary disease) demonstrated that low-dose colchicine reduced the primary composite endpoint of cardiovascular death, MI, ischemic stroke, and ischemia-driven coronary revascularization by 31% (HR 0.69; 95% CI 0.57–0.83; p<0.001). The COLCOT trial extended this benefit to patients within 30 days of MI, reducing cardiovascular events by 23%.
Given the emerging evidence for anti-inflammatory therapy in secondary cardiovascular prevention, how are you integrating low-dose colchicine into your post-MI discharge protocols alongside established lipid-lowering and antiplatelet regimens?
Given the emerging evidence for anti-inflammatory therapy in secondary cardiovascular prevention, how are you integrating low-dose colchicine into your post-MI discharge protocols alongside established lipid-lowering and antiplatelet regimens?
-
SACHINKUMAR PANCHALYesterdayI see low-dose colchicine as an adjunct to, rather than a replacement for, established secondary prevention. For selected post-MI patients, particularly those with persistent inflammatory risk despite optimal LDL lowering and guideline-directed therapy, I would consider colchicine after assessing renal function, drug interactions, and infection/GI risks. I’d continue to emphasize high-intensity statin therapy, antiplatelet treatment, blood pressure control, smoking cessation, and lifestyle modification as the foundation.